1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

Senate To Consider User Fee Bill Soon, As Hopes For BCRA Passage With Device Tax Repeal Fade

 
• By Sue Darcey

Sen. Lamar Alexander, R-Tenn., has placed the user fee FDA Reauthorization Act on the Senate legislative calendar, and is just waiting on a nod from the chamber leadership to bring it up for consideration on the floor. On July 18, after successfully passing an Agriculture/FDA funding bill for 2018 onto the full committee, Ag/FDA Subcommittee Chair John Hoeven, R-N.D., characterized FDARA as non-controversial and ripe for passage. Meanwhile, industries' hopes for device tax repeal as part of legislation repealing the Affordable Care Act are fading away.

Sen. Lamar Alexander, R-Tenn., placed the House-passed device and drug user fee bill, the FDA Reauthorization Act, on the Senate's legislative calendar July 17, which means the bill could be brought up for consideration sometime this week.

Also, the second collapse of support for an Affordable Care Act repeal and replacement bill (Better Care Reconciliation Act), including...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 
• By Natasha Barrow

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

Planning To Take Part in MDUFA? FDA Wants To Hear From You

 
• By Brian Bossetta

The US FDA needs to know who wants a seat at the MDUFA negotiations table before discussions can begin. The agency is asking stakeholders to let it know if they plan to participate in the periodic consultation meetings before July 28.

Final Curtain For LDTs? FDA Will Not Appeal District Court Decision To Vacate Final Rule

 
• By Brian Bossetta

The US FDA has given up on its effort to regulate lab-developed tests as medical devices, at least for now. The agency will not appeal a decision from the Eastern District of Texas that tossed out the FDA’s final rule, leaving the agency with few cards.

Industry Execs Talk Tariff Turbulence During MD&M East

 
• By Brian Bossetta

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

More from Policy & Regulation

FDA Commissioner’s Voucher Program Should Include Devices, Transplant Technology Firm Says

 
• By Elizabeth Orr

The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 
• By Natasha Barrow

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

 
• By Amanda Maxwell

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.